Ablation Therapies Emerging As Gentler Approach To Breast Cancer

Use of ablation technology is emerging as a potentially gentler treatment option for breast cancer, and cryo and thermal ablation in particular are on the verge of regulatory approval that could lead to wider use. A growing number of physicians are already using cryotherapy for breast cancer, but without FDA clearance, reimbursement can be a difficult issue.

Treating cancer has always been a complicated balance of targeting the disease as aggressively as necessary without harming the patient. With breast cancer, the proper treatment can be even more delicate as aggressive treatments have included total or partial removal of the breast as well as radiation treatment. However, a growing number of physicians now see a new trend emerging with ablative therapies that are not only less invasive, but that can also be effective in removing cancerous tumors without the need for surgery.

The topic of ablative treatments was discussed at a recent session of the 17th Annual Meeting of the American Society of Breast Surgeons (ASBrS) in April in Dallas. The discussion...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.